Natera, Inc. (NTRA)
Nasdaq · Austin, Texas, USA · Founded 2004 · CEO Steve Chapman
Valuation summary
$59.35 fair value versus $289.92 in the market, a difference of -79.5%. Rated Sell.
| Fair value per share | $59.35 |
| Current share price | $289.92 |
| Upside / downside | -79.5% |
| Bear case | $38.65 |
| Bull case | $90.23 |
| Discount rate (WACC) | 10.4% |
| Terminal growth | 3.20% |
| Market capitalisation | $42B |
| EV / Sales | 14.7x |
About Natera, Inc.
Founded in 2004 by Matthew Rabinowitz and Jonathan Sheena. Steve Chapman has been chief executive since 2019. Natera runs genetic tests on fragments of DNA found in a blood sample. Panorama screens pregnancies for chromosomal conditions, Signatera checks cancer patients after treatment for traces of tumour DNA that signal a relapse, and Prospera monitors organ transplants. Signatera volumes have been growing very quickly.
Investment case
- The leader in tests that detect cancer recurrence from blood, a young and fast-growing market.
- Insurance coverage keeps widening to more cancer types.
- Has turned cash-flow positive as volumes scale.
Key risks
- Revenue depends on what insurers and Medicare agree to pay.
- Guardant, Exact Sciences and others are competing in cancer testing.
- Patent disputes with rivals are ongoing.
Revenue by segment
| Testing (women's health, oncology, organ health) | 99% |
| Licensing and other | 1% |
Five-year forecast
| Revenue | Free cash flow | |
|---|---|---|
| Year 1 | $3.7B | $0.2B |
| Year 2 | $4.9B | $0.3B |
| Year 3 | $6.1B | $0.4B |
| Year 4 | $7.1B | $0.5B |
| Year 5 | $7.7B | $0.5B |
What the street says
A favourite growth stock in diagnostics; the valuation assumes years of rapid expansion.
Comparable companies: ALNY · HUM · CNC · TEM · DXCM · ARGX · MDLN · HIMS
Open the interactive model, price chart and sensitivity grid →